ABBIE KALEM: Open Payments
NPI 1992304885 · FLOWOOD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,210 in 78 payments from 11 companies in 2025. Trend: 2023 $349 · 2024 $694 · 2025 $2,210
Food & beverage: $2,099Education: $110
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 19 | $734 |
| Janssen Scientific Affairs, LLC | 9 | $514 |
| ABBVIE INC. | 20 | $406 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $192 |
| Madrigal Pharmaceuticals | 5 | $116 |
| PFIZER INC. | 4 | $86 |
| Phathom Pharmaceuticals, Inc. | 2 | $47 |
| Celltrion USA Inc. | 3 | $44 |
| Intercept Pharmaceuticals, Inc. | 2 | $36 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
Products named: TREMFYA, RINVOQ, ENTYVIO, REZDIFFRA, VELSIPITY, VOQUEZNA, VEGZELMA, OCALIVA.
Industry payments across MS — which companies pay providers there.
